Post Marketing Study on Pluvicto in Korea

Launched by NOVARTIS PHARMACEUTICALS · Jul 17, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a medication called Pluvicto, which is used to treat metastatic castration-resistant prostate cancer, a type of advanced prostate cancer that doesn't respond to hormone therapy. The study is being conducted in South Korea and aims to gather more information about how well this treatment works and its effects on patients.

To participate in this trial, men aged 18 and older who are either currently receiving Pluvicto or have plans to start treatment can sign up, provided they give their written consent to join the study. However, individuals who cannot access their medical records or are unwilling to provide consent will not be eligible. Participants in the trial can expect close monitoring and support as they undergo treatment, contributing valuable information that may help improve care for others with this condition in the future.

Gender

MALE

Eligibility criteria

• • Inclusion criteria
• Study participants eligible for inclusion in this study must meet all of the following criteria:
• • 1. Male adult patient age ≥ 18
• • 2. Subject who are being treated with Pluvicto or whose treatment plan is finalized and scheduled to be administered at the time of consent by physician in accordance with the approved indication in South Korea
• • 3. Subject who provided the written informed consent prior to the study enrollment
• • Exclusion criteria
• Study participants meeting any of the following criteria are not eligible for inclusion in this study:
• • 1. Subject whose medical record is not accessible
• • 2. Subject who is not willing to provide the informed consent